Five-year results of nivolumab for the treatment of non-small cell lung cancer in clinical practice of the N.N. Blokhin Russian Cancer Research Center

Five-year results of nivolumab for the treatment of non-small cell lung cancer in clinical practice of the N.N. Blokhin Russian Cancer Research Center

Introduction. Lung cancer remains the one of the most common and fatal cancers in the world. For a long time, chemotherapy was the only treatment option for metastatic lung cancer. Currently, immunotherapy became the one of the preferred options of treatment.The purpose of our work was to evaluate t...

Full description

Bibliographic Details
Main Authors: D. I. Yudin, K. K. Laktionov, K. A. Sarantseva, V. V. Breder, M. S. Ardzinba, E. V. Reutova, O. I. Borisova
Format: Article
Language:Russian
Published: Remedium Group LLC 2021-08-01
Series:Медицинский совет
Subjects:
immunotherapy
non-small cell lung cancer
checkpoint inhibitors
nivolumab
Online Access:https://www.med-sovet.pro/jour/article/view/6244

Similar Items

Similar Items